Ribonucleotide reductase inhibition: regulation of the radiosensitive phenotype via NF kappa B and Bcl-2.
Dent
Paul
P
Department of Radiation Oncology, Virginia Commonwealth University, Richmond, VA 23298-0058, USA.
D000970:Antineoplastic Agents / Q000627:therapeutic use; D002470:Cell Survival / Q000187:drug effects / Q000528:radiation effects; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D006877:Hydroxamic Acids / Q000627:therapeutic use*; D008297:Male; D016328:NF-kappa B / Q000187:drug effects / Q000378:metabolism* / Q000528:radiation effects; D010641:Phenotype; D011471:Prostatic Neoplasms / Q000201:enzymology* / Q000235:genetics / Q000378:metabolism / Q000532:radiotherapy*; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000037:antagonists & inhibitors* / Q000528:radiation effects; D011836:Radiation Tolerance
D000970:Antineoplastic Agents; D006877:Hydroxamic Acids; D016328:NF-kappa B; D019253:Proto-Oncogene Proteins c-bcl-2; C035419:3,4-dihydroxybenzohydroxamic acid